Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

85.40
+0.47000.55%
Post-market: 85.400.00000.00%18:44 EDT
Volume:690.93K
Turnover:58.44M
Market Cap:6.97B
PE:-23.14
High:85.65
Open:82.78
Low:82.67
Close:84.93
52wk High:103.00
52wk Low:19.45
Shares:81.64M
Float Shares:54.63M
Volume Ratio:0.86
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6900
EPS(LYR):-3.6900
ROE:-25.78%
ROA:-15.87%
PB:4.41
PE(LYR):-23.14

Loading ...

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

GlobeNewswire
·
Jan 13

A Look At Kymera Therapeutics (KYMR) Valuation After KT-621 Trial Update And J.P. Morgan Conference Focus

Simply Wall St.
·
Jan 12

Kymera Therapeutics Cut to Peer Perform From Outperform by Wolfe Research

Dow Jones
·
Jan 06

Kymera Therapeutics CEO Nello Mainolfi Reports Sale of Common Shares

Reuters
·
Jan 01

Did KT-621 Fast Track Status Just Shift Kymera Therapeutics' (KYMR) Investment Narrative?

Simply Wall St.
·
Dec 22, 2025

Kymera Therapeutics Inc : B. Riley Raises Target Price to $117 From $80

THOMSON REUTERS
·
Dec 22, 2025

B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating

MT Newswires Live
·
Dec 22, 2025

Kymera Therapeutics (KYMR): Valuation Check After KT-621 Phase 1b Success and FDA Fast Track Nod

Simply Wall St.
·
Dec 21, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Spotify, Robinhood Markets, Cannabis stocks

Reuters
·
Dec 17, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Jabil, Texas Pacific Land, Texas Roadhouse

Reuters
·
Dec 17, 2025

BUZZ-RBC says biotech sector's rebound has momentum, with intriguing opportunities for 2026

Reuters
·
Dec 17, 2025

Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says

MT Newswires Live
·
Dec 17, 2025

Kymera Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Dec 16, 2025

RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Dec 16, 2025

Director Bruce Booth Reports Disposal of Kymera Therapeutics Inc. Common Shares

Reuters
·
Dec 13, 2025

S&P 500 Futures Drop In Premarket Trading; Fermi, Broadcom Lag

Dow Jones
·
Dec 12, 2025

Baker Bros. Advisors LP Reports Acquisition of Kymera Therapeutics Inc. Common Shares

Reuters
·
Dec 12, 2025

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire
·
Dec 12, 2025

FDA Grants Fast Track Designation to Kymera Therapeutics’ KT-621 for Atopic Dermatitis

Reuters
·
Dec 11, 2025

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral Stat6 Degrader for the Treatment of Atopic Dermatitis

THOMSON REUTERS
·
Dec 11, 2025